金域醫學(603882.SH):向激勵對象授予700萬份股票期權
格隆匯 9 月 8日丨金域醫學(603882.SH)公佈,公司於2020年9月8日召開第二屆董事會第十七次會議、第二屆監事會第十七次會議,審議通過了《關於公司2020年股票期權激勵計劃向激勵對象授予股票期權的議案》。
經公司董事會認真核查,認為公司及本次擬授予的激勵對象均未發生上述不得授予股票期權的情況,本次激勵計劃的授予條件已經成就,確定向符合授予條件的157名激勵對象授予700萬份股票期權。
行權價格91.23元/股。股票期權行權前如公司發生資本公積轉增股本、派發股票紅利、股份拆細或縮股、配股、派息等除權、除息事宜,相應行權價格將參照相關規定進行調整。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.